The Effect of <italic style="font-style: italic">Fuzheng Huaji Formula</italic> （扶正化积方） for Chronic Hepatitis B on Reduction of the Incidence of Liver Cirrhosis and Hepatocellular Carcinoma：A Retrospective Cohort Study

YU Simiao; LI Jiahui; JING Jing; HE Tingting; SUN Yongqiang; WANG Liping; ZHANG Aozhe; XIAO Xiaohe; DING Xia; WANG Ruilin

doi:10.13288/j.11-2166/r.2025.03.010

您当前的位置：

首页 >

文章列表页 >

The Effect of Fuzheng Huaji Formula （扶正化积方） for Chronic Hepatitis B on Reduction of the Incidence of Liver Cirrhosis and Hepatocellular Carcinoma：A Retrospective Cohort Study

更新时间：2025-01-26

- The Effect of Fuzheng Huaji Formula （扶正化积方） for Chronic Hepatitis B on Reduction of the Incidence of Liver Cirrhosis and Hepatocellular Carcinoma：A Retrospective Cohort Study
- Journal of Traditional Chinese Medicine Vol. 66, Issue 3, Pages: 268-274(2025)
- 作者机构：
  
  1.中国人民解放军总医院第五医学中心，北京市丰台区西四环中路100号，100039
  2.北京中医药大学中医学院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2025.03.010
  CLC：
- Received：21 August 2024，
  
  Revised：2024-11-30，
  
  Published：02 February 2025
- 稿件说明：
移动端阅览
余思邈,李佳辉,景婧等.扶正化积方干预慢性乙型肝炎降低肝硬化及肝癌发生率的回顾性队列研究[J].中医杂志,2025,66(03):268-274.

YU Simiao,LI Jiahui,JING Jing,et al.The Effect of Fuzheng Huaji Formula （扶正化积方） for Chronic Hepatitis B on Reduction of the Incidence of Liver Cirrhosis and Hepatocellular Carcinoma：A Retrospective Cohort Study[J].Journal of Traditional Chinese Medicine,2025,66(03):268-274.
余思邈,李佳辉,景婧等.扶正化积方干预慢性乙型肝炎降低肝硬化及肝癌发生率的回顾性队列研究[J].中医杂志,2025,66(03):268-274. DOI： 10.13288/j.11-2166/r.2025.03.010.

YU Simiao,LI Jiahui,JING Jing,et al.The Effect of Fuzheng Huaji Formula （扶正化积方） for Chronic Hepatitis B on Reduction of the Incidence of Liver Cirrhosis and Hepatocellular Carcinoma：A Retrospective Cohort Study[J].Journal of Traditional Chinese Medicine,2025,66(03):268-274. DOI： 10.13288/j.11-2166/r.2025.03.010.

摘要

目的

探索扶正化积方干预慢性乙型肝炎以降低肝硬化及肝癌发生率的临床有效性。

方法

采用回顾性队列研究，收集2014年1月1日—2018年12月31日就诊的118例慢性乙型肝炎和234例乙型肝炎肝硬化患者的病历资料。以扶正化积方治疗作为暴露因素，将接受抗乙型肝炎病毒治疗且未联合扶正化积方治疗的患者纳入西药组，将接受抗乙型肝炎病毒治疗且联合服用扶正化积方累积治疗时间≥3个月的患者纳入联合治疗组。随访观察时间设为5年，使用Kaplan-Meier生存分析对慢性乙型肝炎患者肝硬化的累积发生率及乙型肝炎肝硬化患者肝癌的累积发生率进行分析。利用单因素和多因素Cox回归分析对影响肝硬化及肝癌发生的影响因素进行分析。

结果

慢性乙型肝炎患者中联合治疗组55例、西药组63例；乙型肝炎肝硬化患者中联合治疗组110例、西药组124例。慢性乙型肝炎患者5年随访结局情况：联合治疗组肝硬化累积发生率为5.45%（3/55），西药组肝硬化累积发生率为17.46%（11/63），两组比较差异有统计学意义（

=2.003，

=0.045）。乙型肝炎肝硬化患者5年随访结局情况：联合治疗组肝癌累积发生率8.18%（9/110），西药组肝癌累积发生率22.58%（28/124），两组比较差异有统计学意义（

=3.007，

=0.003）。单因素和多因素Cox回归分析均表明，扶正化积方治疗是预防慢性乙型肝炎进展为肝硬化及乙型肝炎肝硬化进展为肝癌的独立保护因素（

＜0.05）。

结论

在抗乙型肝炎病毒治疗基础上联合扶正化积方能够有效干预慢性乙型肝炎的疾病进程，降低肝硬化及肝癌发生率。

Abstract

Objective

To evaluate the clinical effic

acy of

Fuzheng Huaji Formula

（扶正化积方） for chronic hepatitis B to reduce the incidence of liver cirrhosis and hepatocellular carcinoma.

Methods

A retrospective cohort study was conducted， collecting medical records of 118 patients with chronic hepatitis B and 234 patients with hepatitis B-related cirrhosis who visited the hospital between January 1， 2014， and December 31， 2018. The use of

Fuzheng Huaji Formula

was designated as the exposure factor. Patients receiving antiviral treatment for hepatitis B without concurrent

Fuzheng Huaji Formula

therapy were included in the western medicine group， while those receiving antiviral treatment combined with

Fuzheng Huaji Formula

for a cumulative treatment lasting longer than 3 months were included in the combined treatment group. The follow-up observation period was five years. Kaplan-Meier survival analysis was used to assess the cumulative incidence of cirrhosis in patients with chronic hepatitis B and the cumulative incidence of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis. Univariate and multivariate Cox regression analyses were employed to examine the factors influencing the occurrence of cirrhosis and hepatocellular carcinoma.

Results

Among patients with chronic hepatitis B， there were 55 cases in the combined treatment group and 63 cases in the western medicine group； among patients with hepatitis B-related cirrhosis， there were 110 cases in the combined treatment group and 124 cases in the western medicine group. Five-year follow-up outcomes for chronic hepatitis B patients showed that the cumulative incidence of cirrhosis was 5.45% （3/55） in the combined treatment group and 17.46% （11/63） in the western medicine group， with a statistically significant difference between groups （

= 2.003，

= 0.045）. Five-year follow-up outcomes for hepatitis B-related cirrhosis patients showe

d that the cumulative incidence of hepatocellular carcinoma was 8.18% （9/110） in the combined treatment group and 22.58% （28/124） in the western medicine group， also showing a statistically significant difference （

= 3.007，

= 0.003）. Univariate and multivariate Cox regression analyses indicated that treatment with

Fuzheng Huaji Formula

is an independent protective factor in preventing the progression of chronic hepatitis B to cirrhosis and the progression of hepatitis B-related cirrhosis to hepatocellular carcinoma （

＜0.05）.

Conclusion

Combining

Fuzheng Huaji Formula

with antiviral therapy for hepatitis B can effectively intervene in the disease progression of chronic hepatitis B， reducing the incidence of cirrhosis and hepatocellular carcinoma.

关键词

Keywords

references

XIE L ， YIN J ， XIA R ， et al . Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis ［J］. Hepatology ， 2018 ， 68 （ 4 ）： 1476 - 1486 .

FATTOVICH G ， BORTOLOTTI F ， DONATO F . Natural history of chronic hepatitis B： special emphasis on disease progression and prognostic factors ［J］. J Hepatol ， 2008 ， 48 （ 2 ）： 335 - 352 .

OMATA M ， CHENG AL ， KOKUDO N ， et al . Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma： a 2017 update ［J］. Hepatol Int ， 2017 ， 11 （ 4 ）： 317 - 370 .

中华医学会肝病学分会，中华医学会感染病学分会 . 慢性乙型肝炎防治指南（2022年版）［J］. 实用肝脏病杂志， 2023 ， 26 （ 3 ）： 457 - 478 .

PAPATHEODORIDIS GV ， CHAN HL ， HANSEN BE ， et al . Risk of hepatocellular carcinoma in chronic hepatitis B： assessment and modification with current antiviral therapy ［J］. J Hepatol ， 2015 ， 62 （ 4 ）： 956 - 967 .

TSAI TY ， LIVNEH H ， HUNG TH ， et al . Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B： a nationwide population-based cohort study ［J］. BMJ Open ， 2017 ， 7 （ 1 ）： e014571 .

SHI K ， LIU Y ， WANG X ， et al . Adjuvant Fuzheng Huayu Capsule reduces the incidence of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis ［J］. Evid Based Complement Alternat Med ， 2020 ， 2020 ： 8826091 . doi： 10.1155/2020/8826091 http://dx.doi.org/10.1155/2020/8826091 .

JI D ， CHEN Y ， BI J ， et al . Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B ［J］. J Hepatol ， 2022 ， 77 （ 6 ）： 1515 - 1524 .

国家卫生健康委办公厅 . 原发性肝癌诊疗指南（2022年版）［J］. 临床肝胆病杂志， 2022 ， 38 （ 2 ）： 288 - 303 .

ZOU H ， LI M ， LEI Q ， et al . Economic burden and quality of life of hepatocellular carcinoma in greater China： a systematic review ［J］. Front Public Health ， 2022 ， 10 ： 801981 . doi： 10.3389/fpubh.2022.801981 http://dx.doi.org/10.3389/fpubh.2022.801981 .

CAO W ， CHEN HD ， YU YW ， et al . Changing profiles of cancer burden worldwide and in China： a secondary analysis of the global cancer statistics 2020 ［J］. Chin Med J （Engl）， 2021 ， 134 （ 7 ）： 783 - 791 .

COLOTTA F ， ALLAVENA P ， SICA A ， et al . Cancer-related inflammation， the seventh hallmark of cancer： links to genetic instability ［J］. Carcinogenesis ， 2009 ， 30 （ 7 ）： 1073 - 1081 .

刘文斌，曹广文 . 癌症进化发育学：基于炎-癌转化研究的新学说［J］. 中国肿瘤生物治疗杂志， 2017 ， 24 （ 2 ）： 103 - 111 .

FORNER A ， REIG M ， BRUIX J . Hepatocellular carcinoma ［J］. Lancet ， 2018 ， 391 （ 10127 ）： 1301 - 1314 .

XU W ， YU J ， WONG VW . Mechanism and prediction of HCC development in HBV infection ［J］. Best Pract Res Clin Gastroenterol ， 2017 ， 31 （ 3 ）： 291 - 298 .

LIN Y ， ZHENG L ， FANG K ， et al . Proportion of liver cancer cases and deaths attributable to potentially modifiable risk factors in China ［J］. Int J Epidemiol ， 2023 ， 52 （ 6 ）： 1805 - 1814 .

KIM WR ， LOOMBA R ， BERG T ， et al . Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B ［J］. Cancer ， 2015 ， 121 （ 20 ）： 3631 - 3638 .

HOU JL ， ZHAO W ， LEE C ， et al . Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries ［J］. Clin Gastroenterol Hepatol ， 2020 ， 18 （ 2 ）： 457 - 467 .

FANNING GC ， ZOULIM F ， HOU J ， et al . Therapeutic strategies for hepatitis B virus infection： towards a cure ［J］. Nat Rev Drug Disco ， 2019 ， 18 （ 11 ）： 827 - 844 .

宁麟，孙建光 . 原发性肝癌癌前病变中西医研究进展［J］. 世界科学技术-中医药现代化， 2021 ， 23 （ 10 ）： 3590 - 3598 .

赵志敏，李正鑫，朱亭亭，等 . 中医药改善乙型肝炎肝硬化血管重塑研究思路［J］. 中医杂志， 2020 ， 61 （ 15 ）： 1318 - 1321 .

叶永安，靳茜，李小科，等 . 谈慢性肝病“郁、虚、湿、毒、瘀”病机理论［J］. 世界中医药， 2023 ， 23 （ 10 ）： 1 - 9 .

程海波，沈卫星 . 癌毒病机理论与炎癌转变［J］. 中国中西医结合杂志， 2015 ， 35 （ 2 ）： 243 - 246 .

余思邈，丁霞，李萍，等 . 慢性乙型肝炎恶性转化过程证候、证素演变规律的临床研究［J］. 中医杂志， 2023 ， 64 （ 23 ）： 2427 - 2434 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Traditional Chinese Medicine Triple Therapy on Intestinal Mucosal Barrier and Inflammatory Factors in Liver Cirrhosis Patients of Spontaneous Bacterial Peritonitis with the Syndrome of Damp-Heat Stagnated with Toxin and Blood Stasis

Research Path and Paradigm of Digitization and Intelligentization of Ancient TCM Books Based on the Deep Integration of Knowledge Element Theory and Clinical Needs

Staged Differentiation and Treatment of Liver Cirrhosis with Newly Modified Chaihu Biejia Decoction （柴胡鳖甲汤）

Evolutionary Law of Syndrome and Syndrome Elements during the Malignant Transformation of Chronic Hepatitis B

Umbilical Venting and Urination Promoting Patch As Adjuvant Treatment for the Refractory Ascites of Cirrhosis with Blood Stasis and Water Retention in 36 Cases

Related Author

ZHANG Xiaorui

LIU Guangwei

LIU Jiangkai

ZHANG Jianwen

YANG Feng

ZHANG Yi

TAO Xiaohua

LI Jianfeng

Related Institution

Henan University of Chinese Medicine

The First Affiliated Hospital of Henan University of Chinese Medicine

Anhui University of Chinese Medicine

China Institute for History of Chinese Medicine and Medical Literature，China Academy of Chinese Medical Sciences

Guangxi University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

The Effect of Fuzheng Huaji Formula （扶正化积方） for Chronic Hepatitis B on Reduction of the Incidence of Liver Cirrhosis and Hepatocellular Carcinoma：A Retrospective Cohort Study

DOI：10.13288/j.11-2166/r.2025.03.010

摘要

Abstract

关键词

Keywords

references